IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
Shigeru Kotake(Tokyo Women's Medical University), Tatsuo Suda(SHOWA Medical University), Matthew T. Gillespie(Hudson Institute of Medical Research), T. John Martin(The Open University), Kanami Itoh(SHOWA Medical University), Kenichiro MATSUZAKI(Kindai University), Naoyuki Kamatani(Genetic Analysis (Norway)), Naoyuki Takahashi(SHOWA Medical University), Kazuhiko Inoue(Tokyo Women's Medical University Adachi Medical Center), Seiji Saito(Tokyo Women's Medical University), Shigeru Ishiyama(Tokyo Women's Medical University), Nobuyuki Udagawa(Matsumoto Dental University)
Cited by 1,690
Related Papers
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
|Proceedings of the National Academy of Sciences|1998|4.3k
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
|Endocrine Reviews|1999|2.3k
Tumor Necrosis Factor α Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl–Rank Interaction
|The Journal of Experimental Medicine|2000|1.3k
OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION
|Endocrinology|1988|945
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
|Journal of Bone and Mineral Research|1996|548